In these cases, CFTD is considered distinct muscle disease. Respiratory compromise is a common feature of critical illness myopathy, amyloid myopathy, interstitial lung disease associated with dermatomyositis, acid maltase deficiency, and, very rarely, a subtype of limb girdle muscular dystrophy LGMD 2I. Moreover, there has been no report of overlap between the two disorders with respect to histologic findings i. Ann Neurol. This is performed by obtaining baseline serum ammonia and lactate levels taken from the forearm.
Central core disease/malignant hyperthermia susceptibilty
NCBI Bookshelf. Central core disease CCD is characterized by muscle weakness ranging from mild to severe. Most affected individuals have mild disease with symmetric proximal muscle weakness and variable involvement of facial and neck muscles. The extraocular muscles are often spared. Motor development is usually delayed, but in general, most affected individuals acquire independent ambulation. Life span is usually normal. Severe disease is early in onset with profound hypotonia often accompanied by poor fetal movement, spinal deformities, hip dislocation, joint contractures, poor suck, and respiratory insufficiency requiring assisted ventilation.
More from Genetics Home Reference
This table lists symptoms that people with this disease may have. For most diseases, symptoms will vary from person to person. People with the same disease may not have all the symptoms listed. The HPO collects information on symptoms that have been described in medical resources. The HPO is updated regularly. If you need medical advice, you can look for doctors or other healthcare professionals who have experience with this disease.
Central core disease CCD , also known as central core myopathy , is an autosomal dominant  congenital myopathy inborn muscle disorder. It was first described by Shy and Magee in Symptoms may be present at birth or may appear at any stage of life. There appears to be a growing number of people who do not become symptomatic until adulthood to middle age. While generally not progressive, again there appears to be a growing number of people who do experience a slow clinically significant progression of symptomatology. These cases may hypothetically be due to the large number of gene mutations of ryanodine receptor malfunction, and with continued research may in fact be found to be clinical variants.